This study is being performed in two parts. The aim of the first part is to establish the safety and best tolerated dose of the investigational drug called PG545 in combination with Nivolumab, administered via Intravenous Infusion, in participants with advanced cancer. If the combination is shown to be well tolerated the second part of the study will explore the anti-cancer effects of the combination in patients with pancreatic cancer.

Nivolumab (Opdivo®) has been approved in Australia by the Therapeutic Goods Administration (TGA) as a single agent, for the treatment of patients with unresectable or metastatic melanoma, advanced non-small cell lung cancer, advanced clear cell renal cell, and in combination with Yervoy (ipilimumab), for melanoma.

PG545 is an experimental treatment. This means it is not an approved treatment for cancer in Australia. The safety and tolerability of PG545 administered by IV infusion has been previously tested in twenty-three (23) people with advanced cancer. If you choose to participate, you will be treated with both PG545 and Nivolumab. This combination has not been used in patients before.

You may be eligible if you:

• for Part 1 if you have a solid tumour that has progressed after standard treatment.
• for Part 2 if you have metastatic pancreatic cancer

Study code: S17ZUC05
When enquiring about this clinical study please quote the study code above

This clinical study is currently recruiting.

If you would like more information, register below or call 1800 727 874.